ArticleImmunity, inflammation and disease2026
Analgesic and Antidiarrheal Properties of Lappaconitine, Possibly Through Cyclooxygenase and µ-Opioid Receptor Interaction Pathways: In Vivo and In Silico Studies.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Analgesic and Antidiarrheal Properties of Lappaconitine, Possibly Through Cyclooxygenase and µ-Opioid Receptor Interaction Pathways: In Vivo and In Silico Studies.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLappaconitine (LAP) is a diterpenoid alkaloid with strong anti-inflammatory activity. However, there is limited information on its gastroprotective effects. The present study aimed to explore the analgesic and antidiarrheal effects of LAP through in vivo and in silico studies.
methodsFor this, LAP was administered orally to Swiss albino mice at doses of 1 and 4 mg/kg (bw). The analgesic effect was assessed using the acetic acid-induced writhing test. Simultaneously, antidiarrheal activity was evaluated using the castor oil-induced diarrheal secretion test in mice. In addition, an in silico molecular docking analysis was conducted to forecast the participation of cyclooxygenases (COXs) and the µ-opioid receptor.
resultsAccording to our in vivo findings, LAP and combination therapy (LAP + diclofenac sodium) significantly (p < 0.05) alleviated the number of writhing episodes in the experimental animals compared to the control group. Furthermore, in the castor oil-induced diarrhea model, LAP and combination therapy (LAP + loperamide) significantly (p < 0.05) prolonged the onset time of diarrhea and reduced the number of diarrheal secretions. Besides, the molecular docking study suggested that LAP showed better binding affinity (-8.2 and -7.8 kcal/mol) with COX-1 and COX-2 enzymes, respectively. Likewise, LAP exhibited the highest binding score (-9.8 kcal/mol) with the µ-opioid receptor. Moreover, LAP demonstrated high gastrointestinal absorption with low toxicity.
conclusionTherefore, LAP exerts potential analgesic and antidiarrheal effects, as well as synergistic properties with diclofenac sodium and loperamide through the cyclooxygenase and MOR interaction pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.